PDT Partners LLC Increases Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

PDT Partners LLC raised its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 28.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 188,803 shares of the company's stock after purchasing an additional 41,641 shares during the period. PDT Partners LLC owned 0.33% of Ginkgo Bioworks worth $1,854,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Schonfeld Strategic Advisors LLC bought a new position in Ginkgo Bioworks in the fourth quarter worth about $1,000,000. Northern Trust Corp grew its position in shares of Ginkgo Bioworks by 11.5% in the 4th quarter. Northern Trust Corp now owns 94,876 shares of the company's stock worth $932,000 after buying an additional 9,791 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Ginkgo Bioworks during the fourth quarter valued at approximately $1,796,000. Price T Rowe Associates Inc. MD lifted its position in Ginkgo Bioworks by 4.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock valued at $814,000 after acquiring an additional 3,152 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at approximately $665,000. Institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Trading Down 0.9 %

Shares of DNA stock traded down $0.07 during trading hours on Monday, reaching $6.98. 336,809 shares of the company's stock were exchanged, compared to its average volume of 1,474,093. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $41.20. The stock's 50 day moving average is $7.24 and its 200-day moving average is $9.14. The company has a market cap of $404.79 million, a price-to-earnings ratio of -0.53 and a beta of 1.29.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.